The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is one to consider buying after jumping 9.2% higher on Thursday.
The post Up 9.2% in 1 day, is the Clinuvel Pharmaceuticals (ASX:CUV) share price a buy? appeared first on Motley Fool Australia. –
So, what’s causing a surge in Aussie pharma shares like Clinuvel and is it still in the buy zone?
What does Clinuvel Pharmaceuticals do?
Clinuvel is an Australian-headquartered, global pharmaceutical company. The group focuses on developing and delivering treatments for patients “with a range of severe genetic and skin disorders”.
The company has operations across photomedicine, pharmaceutical and photocare within the broader industry.
As at Thursday’s close, the Clinuvel share price was trading at $21.51 per share with a market capitalisation of $1.1 billion.
Why did the Clinuvel Pharmaceuticals share price surge higher?
The big announcement yesterday was an expansion of Clinuvel’s SCENESSE drug (afamelanotide 16mg) to treat the disease xeroderma pigmentosum (XP).
Clinuvel has made great strides in the development and application of SCENESSE for a number of years. Yesterday’s announcement is the latest step as it looks to treat XP, a rare genetic disorder affecting one in one million people in the USA and Europe.
That was good news for shareholders who were quick to buy in and bid up the Clinuvel Pharmaceuticals share price.
Is the Aussie pharma share still in the buy zone?
Despite yesterday’s surge, the Clinuvel Pharmaceuticals share price is down 24.9% for the year.
Given that it also trades at a price to earnings (P/E) ratio of 65.2, I’m not sure I’m keen on buying just yet.
Thursday’s announcement was a promising step but I think I’d like to see more positive test results before buying.
In the meantime, I think there are some other strong candidates in the biotech and pharmaceuticals sector.
Personally, I like the look of Polynovo Ltd (ASX: PNV) as it expands into new, lucrative markets with its NovoSorb BTM technology.
These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
- 5 things to watch on the ASX 200 on Friday
- 2 exciting ASX growth shares to buy in September
- ASX 200 rises 0.5%, gold miners glitter
- Why the Rio Tinto share price is outperforming its peers
- Is the Wesfarmers (ASX:WES) share price a quality buy for ASX dividends?
Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.